US Patent

US11965040 — Modulation of complement activity

Formulation · Assigned to Ra Pharmaceuticals Inc · Expires 2035-06-12 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects modulators of complement activity and methods of using them as therapeutics.

USPTO Abstract

The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Drugs covered by this patent

zilucoplan-sodium (ZILUCOPLAN SODIUM)

Patent Metadata

Patent number: US11965040
Jurisdiction: US
Classification: Formulation
Expires: 2035-06-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Ra Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.